Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3076447 | 1.00 | BRD4 (0.40) | BRD4CHRM2CHRM4CHRM5ELANE | |
| SCHEMBL3076448 | 1.00 | BRD4 (0.40) | BRD4CHRM2CHRM4CHRM5ELANE | |
| SCHEMBL15720848 | 0.78 | CHRM2 (0.47) | CHRM2CHRM4CHRM5ALDH1A1MEN1 | |
| SCHEMBL24699789 | 0.71 | KMT2A (0.48) | BRD4CHRM2CHRM4CHRM5ELANE | |
| SCHEMBL22599709 | 0.71 | CHRM2 (0.46) | BRD4CHRM2CHRM4CHRM5ELANE | |
| SCHEMBL3061199 | 0.71 | KMT2A (0.48) | BRD4CHRM2CHRM4CHRM5ELANE | |
| SCHEMBL13303749 | 0.71 | ALDH1A1 (0.35) | ALDH1A1NPSR1MEN1KMT2A | |
| SCHEMBL27043869 | 0.70 | BRD4 (0.43) | BRD4CHRM2CHRM4CHRM5ALDH1A1 | |
| SCHEMBL3382821 | 0.70 | FUCA1 (0.45) | CHRM2CHRM4CHRM5ALDH1A1SIGMAR1 | |
| SCHEMBL9204180 | 0.70 | TMEM97 (0.43) | SIGMAR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267747-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267747-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267747-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-7732609-B2 | 5-(arylsulfonyl)-pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732609-B2 | 5-(arylsulfonyl)-pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732609-B2 | 5-(arylsulfonyl)-pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20070155753-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155753-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155753-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155753-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | PSEN1, PSEN2, C1S | BRD4 490/4885CHRM2 11/4885CHRM4 106/4885 |
| US-20100267747-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | PSEN1, PSEN2, C1S | BRD4 490/4885CHRM2 11/4885CHRM4 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.